48,830
edits
(→IHC) |
|||
Line 109: | Line 109: | ||
*Prognosis: slightly better than other CRC without MSI. | *Prognosis: slightly better than other CRC without MSI. | ||
*Treatment implication: different response to chemotherapy. | *Treatment implication: different response to chemotherapy. | ||
Commonly associated abnormalities in the genes: | |||
#MLH1. | |||
#PMS2. | |||
#MSH2. | |||
#MSH6. | |||
Less common abnormalities: | |||
#PMS1. | |||
#MLH3. | |||
#MSH3. | |||
====MSI classification==== | ====MSI classification==== | ||
Line 134: | Line 144: | ||
===IHC=== | ===IHC=== | ||
Immunostains are commonly done for: | |||
*MLH1. | |||
*PMS2. | |||
*MSH2. | |||
*MSH6. | |||
IHC interpretation: | |||
*Loss of nuclear staining in nuclei of the tumour | *'''Loss of nuclear staining''' in nuclei of the tumour ''implies'' a mutation. | ||
**Nuclear staining = normal. | **Nuclear staining = normal. | ||
Line 155: | Line 161: | ||
*PMS2 & MSH6 can be used as a screen.<ref name=pmid20632815>{{Cite journal | last1 = Hall | first1 = G. | last2 = Clarkson | first2 = A. | last3 = Shi | first3 = A. | last4 = Langford | first4 = E. | last5 = Leung | first5 = H. | last6 = Eckstein | first6 = RP. | last7 = Gill | first7 = AJ. | title = Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. | journal = Pathology | volume = 42 | issue = 5 | pages = 409-13 | month = | year = 2010 | doi = 10.3109/00313025.2010.493871 | PMID = 20632815 }}</ref> | *PMS2 & MSH6 can be used as a screen.<ref name=pmid20632815>{{Cite journal | last1 = Hall | first1 = G. | last2 = Clarkson | first2 = A. | last3 = Shi | first3 = A. | last4 = Langford | first4 = E. | last5 = Leung | first5 = H. | last6 = Eckstein | first6 = RP. | last7 = Gill | first7 = AJ. | title = Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. | journal = Pathology | volume = 42 | issue = 5 | pages = 409-13 | month = | year = 2010 | doi = 10.3109/00313025.2010.493871 | PMID = 20632815 }}</ref> | ||
====Etiology/significance loss of staining==== | |||
*MSH2 mutations (IHC stain -ve) - often associated with a germline mutation,<ref name=pmid16216036>{{cite journal |author=Mangold E, Pagenstecher C, Friedl W, ''et al.'' |title=Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining |journal=J. Pathol. |volume=207 |issue=4 |pages=385–95 |year=2005 |month=December |pmid=16216036 |doi=10.1002/path.1858 |url=}}</ref> while mutations in MLH1 are usually sporatic.<ref>A. Pollett. 2010.</ref> | *MSH2 mutations (IHC stain -ve) - often associated with a germline mutation,<ref name=pmid16216036>{{cite journal |author=Mangold E, Pagenstecher C, Friedl W, ''et al.'' |title=Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining |journal=J. Pathol. |volume=207 |issue=4 |pages=385–95 |year=2005 |month=December |pmid=16216036 |doi=10.1002/path.1858 |url=}}</ref> while mutations in MLH1 are usually sporatic.<ref>A. Pollett. 2010.</ref> | ||
*PMS2 mutations (IHC stain -ve) - often associated with a germline mutation.<ref name=pmid20205264>{{cite journal |author=Vaughn CP, Robles J, Swensen JJ, ''et al.'' |title=Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes |journal=Hum. Mutat. |volume=31 |issue=5 |pages=588–93 |year=2010 |month=May |pmid=20205264 |doi=10.1002/humu.21230 |url=}}</ref> | *PMS2 mutations (IHC stain -ve) - often associated with a germline mutation.<ref name=pmid20205264>{{cite journal |author=Vaughn CP, Robles J, Swensen JJ, ''et al.'' |title=Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes |journal=Hum. Mutat. |volume=31 |issue=5 |pages=588–93 |year=2010 |month=May |pmid=20205264 |doi=10.1002/humu.21230 |url=}}</ref> |
edits